Cogentix Medical Inc (CGNT) : Geduld E E scooped up 123,495 additional shares in Cogentix Medical Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 245,671 shares of Cogentix Medical Inc which is valued at $265,325.Cogentix Medical Inc makes up approximately 0.37% of Geduld E E’s portfolio.
Other Hedge Funds, Including , Gmt Capital Corp boosted its stake in CGNT in the latest quarter, The investment management firm added 6,500 additional shares and now holds a total of 21,860 shares of Cogentix Medical Inc which is valued at $23,609.Perkins Capital Management Inc reduced its stake in CGNT by selling 25,190 shares or 2.42% in the most recent quarter. The Hedge Fund company now holds 1,016,071 shares of CGNT which is valued at $1,056,714. Cogentix Medical Inc makes up approx 1.16% of Perkins Capital Management Inc’s portfolio. Searle sold out all of its stake in CGNT during the most recent quarter. The investment firm sold 10,000 shares of CGNT which is valued $11,500.
Cogentix Medical Inc closed down -0.01 points or -0.93% at $1.06 with 35,471 shares getting traded on Monday. Post opening the session at $1.06, the shares hit an intraday low of $1.05 and an intraday high of $1.15 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Cogentix Medical Inc. formerly Vision-Sciences Inc. is a medical device company. The Company designs develops manufactures and markets products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier EndoSheath technology. The Company produces and markets Endoscopes such as cystoscopes ureteroscopes laryngoscopes otoscopes sinuscopes trans-nasal esophagoscopy (TNE) and bronchoscopes for medical use and borescopes for industrial use and digital processing units (DPU). The Company offers Urgent PC Neuromodulation System a nerve stimulation device that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). It also offers Macroplastique an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence. It markets additional bulking agents: PTQ for the treatment of fecal incontinence and the VOX for vocal cord augmentation.